Back to results
US 2026/0137812 A1Published application
Synthetic cancer-specific promoters
AssigneeEARLI Inc.
InventorsDariusz WODZIAK, Shireen RUDINA, Maggie C. LOUIE, Yue ZHANG, Elizabeth STROEBELE, Albert PARK, David SUHY
Life of this patent
Estimating the term…
Abstract
Described herein are synthetic promoters and/or enhancers that are specific for cancer cells and methods of engineering synthetic cancer-specific promoters.
Claims31
1-60. (canceled)
A method, comprising:
- administering to a subject a composition comprising a nucleic acid encoding an engineered polypeptide, wherein said engineered polypeptide comprises:
- (a) an extracellularly-oriented domain comprising an epitope capable of binding:
- (i) an antibody;
- or (ii) a peptide hormone or growth factor;
- wherein said extracellularly-oriented domain does not comprise an scFv;
- and
- (b) a transmembrane domain or membrane affinity domain capable of associating with an outer membrane of a cell, comprising a transmembrane domain or membrane affinity domain from DLL3, PSMA, SSTR2, PD-L1, EGFR, CD28, CD4, ICOS, or CD73, wherein (a) and (b) are heterologous to each other.
4 more elements
Dependencies are inferred from the claim text.